NeoGenomics Reports Third Quarter 2024 Results
NeoGenomics, Inc. (NEO)
Last neogenomics, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.neogenomics.com
Company Research
Source: Business Wire
Adjusted EBITDA Improves 305%; Fifth Consecutive Quarter of Positive Adjusted EBITDA; Increasing FY Guidance to $37-$40 Million FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2024.Third Quarter 2024 Highlights As Compared To Third Quarter 2023 Consolidated revenue increased 10% to $168 millionClinical Services revenue increased 14% to $146 millionAdvanced Diagnostics revenue decreased 10% to $22 millionNet loss decreased 4% to $18 millionAdjusted EBITDA increased 305% to positive $13 million“We delivered a strong third quarter, again growing revenue by double digits and increasing adjusted EBITDA by over 300%, all while serving a record number of patients,” said Chris Smith, Chief Executive Officer of NeoGenomics. “Our results demonstrate our teammates' commitment to executing on our strategic priorities. This disciplined app
Show less
Read more
Impact Snapshot
Event Time:
NEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEO alerts
High impacting NeoGenomics, Inc. news events
Weekly update
A roundup of the hottest topics
NEO
News
- NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare ConferenceBusiness Wire
- NeoGenomics, Inc. (NASDAQ: NEO) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $19.00 price target on the stock.MarketBeat
- NeoGenomics Third Quarter 2024 Earnings: EPS Beats Expectations [Yahoo! Finance]Yahoo! Finance
- NeoGenomics Inc (NEO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... [Yahoo! Finance]Yahoo! Finance
- NeoGenomics receives New York state approval for its solid tumor test [Seeking Alpha]Seeking Alpha
NEO
Earnings
- 11/5/24 - Beat
NEO
Sec Filings
- 11/5/24 - Form 4
- 11/5/24 - Form 3
- 11/5/24 - Form 10-Q
- NEO's page on the SEC website